Navarro J F, García J, Macía M, Mora C, Chahin J, Gallego E, Méndez M L, del Castillo N
Department of Nephrology, Hospital Ntra. Sra. de Candelaria, S/C de Tenerife, Spain.
Clin Nephrol. 1998 Jun;49(6):370-2.
Erythrocytosis is a relatively common complication of renal transplantation. Recent observations indicate that angiotensin-converting enzyme inhibitors correct renal transplant erythrocytosis. Other drugs to inhibit the renin-angiotensin system have been developed recently. The newest of these is losartan, a specific antagonist of the angiotensin II type I receptor. We report three patients in which the use of losartan controlled posttransplant erythrocytosis. Our findings suggest that losartan can be effective and safe in the treatment of posttransplant erythrocytosis.
